Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Buyout numbers

<< Previous

Bullboard Posts

Next >>

Comment by venture009on Oct 23, 2023 8:22pm

153 Views

Post# 35697391

RE:RE:RE:RE:RE:Buyout numbers

https://www.ft.com/content/99d8bdb4-b854-411f-b3b4-fcb6f94f8292

This article is interesting from the perspective that Roche has not had much success when it comes to aquisitions and PIII, and the market has punished them. They will be very cautious. Should we expect an imminent offer. The $billion question. Let's hope they have had enough experience with pela to make an offer.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale